Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.56 |
| ▸ | TACR1 | P25103 | 5/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | SOD1 | P00441 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862494 | 0.78 | IDO1 (0.61) | IDO1TACR1AGXTMAOBADAM10 | |
| SCHEMBL514759 | 0.77 | IDO1 (0.64) | IDO1AGXTMAOB | |
| SCHEMBL3155758 | 0.75 | IDO1 (0.52) | IDO1TACR1AGXTMAOB | |
| SCHEMBL4801258 | 0.74 | IDO1 (0.56) | IDO1TACR1AGXTMAOBADAM10 | |
| SCHEMBL2095571 | 0.74 | IDO1 (0.58) | IDO1TACR1AGXT | |
| SCHEMBL4800547 | 0.74 | IDO1 (0.58) | IDO1MAOB | |
| SCHEMBL2281030 | 0.70 | IDO1 (0.52) | IDO1TACR1AGXTMAOBMMP2 | |
| SCHEMBL2859240 | 0.69 | IDO1 (0.44) | IDO1AGXT | |
| SCHEMBL4412388 | 0.69 | IDO1 (0.50) | IDO1TACR1AGXTMAOBADAM10 | |
| SCHEMBL4799508 | 0.69 | IDO1 (0.32) | IDO1AGXTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342031-B2 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) | 2007-12-20 | — | — | US | disclosed |
| US-7273879-B2 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-25 | — | — | US | disclosed |
| US-20060014962-A1 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550661-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215578-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | IDO1 890/4885TACR1 1348/4885AGXT 1246/4885 |
| US-20060014962-A1 | Thiadiazole compound and use thereof | CBR3, TH, CYP2E1 | IDO1 446/4885TACR1 2553/4885AGXT 1236/4885 |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | IDO1 912/4885TACR1 1562/4885AGXT 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.